

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.

Conference Details:

Presentation and Q&A

Date:	Monday, January 8, 2024
Time:	5:15 – 5:55 p.m. Pacific Standard Time (PST)
Location:	Westin St. Francis Hotel in San Francisco, California
Moderator:	Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research
Novavax participants:	John C. Jacobs, President and Chief Executive Officer

Conference

Event:	Investor Meetings
Date:	Monday, January 8, 2024

Recordings

A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and [LinkedIn](#) for more information.

Contacts:

Investors

Erika Schultz
240-268-2022
ir@novavax.com

Media

Ali Chartan
240-720-7804
media@novavax.com

SOURCE NOVAVAX, INC